METHODS OF TREATING PULMONARY INJURY WITH CGRP INHIBITORS

1 . A method for treating COVID-19 in a patient in need of such treatment, comprising administering to the patient a therapeutically effective amount of CGRP inhibitor.

2 . The method of claim 1 , wherein the treating the COVID-19 comprises reversing, alleviating, ameliorating, inhibiting, slowing down or preventing the onset, progression, development, severity or recurrence of a symptom, complication or condition, or biochemical indicia associated with pulmonary injury associated with COVID-19 in a the patient.

3 . The method of claim 1 , wherein the treating the COVID-19 comprises preventing pulmonary injury associated with COVID-19 in the patient.

4 . The method of claim 1 , wherein the treating the COVID-19 comprises treating pulmonary edema or neurogenic inflammation associated with COVID-19 in the patient in need of such treatment.

5 . (canceled)

6 . The method of claim 1 , wherein the treating the COVID-19 comprises treating a disorder characterized by upregulation of transient receptor potential channel associated with COVID-19.

7 . The method of claim 1 , wherein the treating the COVID-19 comprises slowing down or preventing transmission of bacterial or viral infection from the patient to another person associated with COVID-19.

8 . The method according to claim 1 , wherein the patient has another pulmonary injury.

9 . The method according to claim 8 , wherein the other pulmonary injury is caused by influenza virus, parainfluenza virus, respiratory syncytial virus, human metapneumoviruses, adenovirus, rhinovirus, enterovirus, hantavirus, coronavirus, or a combination thereof.

10 - 12 . (canceled)

13 . The method according to claim 1 , wherein the CGRP inhibitor comprises a CGRP antibody, a CGRP receptor antibody, an antigen-binding fragment from a CGRP antibody or a CGRP receptor antibody, a CGRP infusion inhibitory protein, a CGRP bio-neutralizing agent, a CGRP receptor antagonist, a small molecule CGRP inhibitor, or a polypeptide CGRP inhibitor.

14 . The method according to claim 13 , wherein the antigen-binding fragment comprises one or both of a heavy chain variable region and a light chain variable region from a CGRP antibody or a CGRP receptor antibody.

15 . (canceled)

16 . (canceled)

17 . The method according to claim 13 , wherein the CGRP antibody is selected from galcanezumab-gnlm, fremanezumab-vfrm, eptinezumab jjmr, and erenumab-aooe.

18 . The method according to claim 13 , wherein the CGRP receptor antagonist is selected from olcegepant, telcagepant, ubrogepant, atogepant, rimegepant, and zavegepant.

19 . The method according to claim 18 , wherein the CGRP receptor antagonist is rimegepant.

20 . The method according to claim 18 , wherein the CGRP receptor antagonist is zavegepant.

21 . The method according to claim 7 , wherein the CGRP inhibitor is administered intranasally or nose-to-brain or by delivery directly to the lungs of the patient.

22 . The method according to claim 1 , further comprising administering an interleukin inhibitor to the patient.

23 - 28 . (canceled)

29 . The method according to claim 1 , further comprising administering an anti-viral agent to the patient.

30 - 33 . (canceled)

34 . (canceled)

35 . The method according to claim 1 , further comprising administering an anti-bacterial agent to the patient.

36 - 38 . (canceled)

39 . A pharmaceutical composition comprising a CGRP inhibitor and at least one selected from an interleukin inhibitor, an anti-viral agent, or an anti-bacterial agent.

40 . A kit for treating a condition associated with pulmonary injury in a patient, the kit comprising:

(a) the pharmaceutical composition of claim 39 ; and

(b) instructions for administering the pharmaceutical composition.

41 . (canceled)